Q-omics provides the consensus-scored SSMEM1 profile across patient tissues and cancer cell-line models. SSMEM1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SSMEM1 is differentially expressed in 9, with the highest sampling consensus in LUAD. Additionally, SSMEM1 RNA expression shows 6,717 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, LUAD, and STAD as cancer lineages where SSMEM1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SSMEM1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SSMEM1 survival associations across molecular data types. SSMEM1 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SSMEM1 RNA expression–survival associations across cancer types. High SSMEM1 expression shows unfavorable associations in ACC, THYM, COAD, KIRC, KICH and CHOL. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SSMEM1 RNA expression.
This table summarizes SSMEM1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for SSMEM1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SSMEM1 shows lower tumor expression in LUAD, LUSC, BRCA, COAD and UCEC and higher tumor expression in LIHC. The LUAD box plot shows higher SSMEM1 RNA expression in normal versus tumor tissue (log2 FC = −0.389, t-test p < 0.001).
This table shows molecular features associated with SSMEM1 in patient tissues and cancer cell lines. In patient samples, SSMEM1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SSMEM1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
